Heterocyclic pynmidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) kinase activity are disclosed. Selectivity in modulation of various EGFR mutant activity has been disclosed. Pharmaceutical compositions comprising the pynmidine derivative, and methods of treatment for diseases associated with EGFR kinase activity including non-small cell lung cancer comprising administration of the pynmidine derivative are disclosed.
